These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29772250)

  • 41. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
    Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and validation of two solid-phase enzyme immunoassays (ELISA) for quantitation of human epidermal growth factors (hEGFs).
    Sizemore N; Dudeck RC; Barksdale CM; Nordblom GD; Mueller WT; McConnell P; Wright DS; Guglietta A; Kuo BS
    Pharm Res; 1996 Jul; 13(7):1088-94. PubMed ID: 8842051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative binding of disulfide-bridged PEG-Fabs.
    Khalili H; Godwin A; Choi JW; Lever R; Brocchini S
    Bioconjug Chem; 2012 Nov; 23(11):2262-77. PubMed ID: 22994419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
    Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
    Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.
    Zhang Y; Yao Z; Kaila N; Kuebler P; Visich J; Maia M; Tuomi L; Ehrlich JS; Rubio RG; Campochiaro PA
    Ophthalmology; 2014 Nov; 121(11):2237-46. PubMed ID: 25001159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
    Bucher F; Parthasarathy A; Bergua A; Onderka J; Regenfuss B; Cursiefen C; Bock F
    Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
    Barzelay A; Lowenstein A; George J; Barak A
    Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK; Moon HJ
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of a Gyrolab™ assay for quantification of rituximab in human serum.
    Liu XF; Wang X; Weaver RJ; Calliste L; Xia C; He YJ; Chen L
    J Pharmacol Toxicol Methods; 2012; 65(3):107-14. PubMed ID: 22406436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2.
    Jiang J; Xu K; Wang L; Xin W; Zhao G; Huang M; Li S; Luan X; Fang J
    Eur J Pharm Sci; 2018 Aug; 121():251-259. PubMed ID: 29715501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG.
    Wang X; Quarmby V; Ng C; Chuntharapai A; Shek T; Eigenbrot C; Kelley RF; Shia S; McCutcheon K; Lowe J; Leddy C; Coachman K; Cain G; Chu F; Hotzel I; Maia M; Wakshull E; Yang J
    MAbs; 2013; 5(4):540-54. PubMed ID: 23774668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model.
    Christoforidis JB; Briley K; Binzel K; Bhatia P; Wei L; Kumar K; Knopp MV
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5636-5645. PubMed ID: 29094168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.
    Yu DA; You M; Ji WW; Lu Y; Liu B; Yan SS
    Toxicol Lett; 2018 Aug; 292():73-77. PubMed ID: 29709424
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
    Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
    Nuzzi R; Tridico F
    Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis.
    Machalińska A; Paczkowska E; Pabin T; Safranow K; Karczewicz D; Machaliński B
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):471-5. PubMed ID: 21830945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.